{"id":175286,"date":"2023-11-01T14:27:58","date_gmt":"2023-11-01T19:27:58","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/11\/new-nk-cell-engaging-immunotherapy-approaches-to-target-and-potentially-treat-recalcitrant-ovarian-cancer"},"modified":"2023-11-01T14:27:58","modified_gmt":"2023-11-01T19:27:58","slug":"new-nk-cell-engaging-immunotherapy-approaches-to-target-and-potentially-treat-recalcitrant-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/11\/new-nk-cell-engaging-immunotherapy-approaches-to-target-and-potentially-treat-recalcitrant-ovarian-cancer","title":{"rendered":"New NK cell engaging immunotherapy approaches to target and potentially treat recalcitrant ovarian cancer"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/new-nk-cell-engaging-immunotherapy-approaches-to-target-and-potentially-treat-recalcitrant-ovarian-cancer2.jpg\"><\/a><\/p>\n<p>The Wistar Institute\u2019s David B. Weiner and collaborators have engineered novel monoclonal antibodies that engage natural killer (NK) cells through a unique surface receptor that activates the immune system to fight against cancer.<\/p>\n<p>In their publication titled, \u201cSiglec-7 glyco-immune binding MAbs or NK cell engager biologics induce potent anti-tumor immunity against <a href=\"https:\/\/medicalxpress.com\/tags\/ovarian+cancers\/\" rel=\"tag\" class=\"\">ovarian cancers<\/a>,\u201d <a href=\"https:\/\/www.science.org\/doi\/10.1126\/sciadv.adh4379\">published<\/a> in <i>Science Advances<\/i>, the team demonstrates the preclinical feasibility of utilizing these new cancer immunotherapeutic approaches against diverse ovarian cancer types, including treatment-resistant and refractory ovarian cancers\u2014alone or in combination with checkpoint inhibitor treatment.<\/p>\n<p>The research started as a collaboration between Wistar\u2019s Drs. Weiner and Mohamed Abdel-Mohsen, who were exploring the development of new glyco-signaling biologic tools that may be important in the fight against cancer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Wistar Institute\u2019s David B. Weiner and collaborators have engineered novel monoclonal antibodies that engage natural killer (NK) cells through a unique surface receptor that activates the immune system to fight against cancer. In their publication titled, \u201cSiglec-7 glyco-immune binding MAbs or NK cell engager biologics induce potent anti-tumor immunity against ovarian cancers,\u201d published in [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1902,11],"tags":[],"class_list":["post-175286","post","type-post","status-publish","format-standard","hentry","category-bioengineering","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/175286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=175286"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/175286\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=175286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=175286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=175286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}